Vertex Pharmaceuticals is a biotechnology business based in the US. Vertex Pharmaceuticals shares (VRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $483.96 – a decrease of 6.34% over the previous week. Vertex Pharmaceuticals employs 5,400 staff and has a trailing 12-month revenue of around $10.6 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $483.96 |
|---|---|
| 52-week range | $341.90 - $519.88 |
| 50-day moving average | $475.40 |
| 200-day moving average | $452.28 |
| Wall St. target price | $515.77 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.91 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $494.61 from 2024-11-13
| 1 week (2024-11-08) | -4.28% |
|---|---|
| 1 month (2024-10-16) | 1.51% |
| 3 months (2024-08-16) | 3.61% |
| 6 months (2024-05-16) | 12.25% |
| 1 year (2023-11-16) | 44.20% |
|---|---|
| 2 years (2022-11-16) | 61.93% |
| 3 years (2021-11-16) | 162.63% |
| 5 years (2019-11-15) | 135.75% |
Valuing Vertex Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vertex Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vertex Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3545. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Vertex Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Vertex Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.4 billion.
The EBITDA is a measure of a Vertex Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $10.6 billion |
|---|---|
| Operating margin TTM | 40.82% |
| Gross profit TTM | $5.3 billion |
| Return on assets TTM | 12.05% |
| Return on equity TTM | -2.98% |
| Profit margin | -4.51% |
| Book value | $60.65 |
| Market Capitalization | $133.1 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Vertex Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 30.84
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Vertex Pharmaceuticals's overall score of 30.84 (as at 12/31/2018) is nothing to write home about – landing it in it in the 44th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Vertex Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.65/100
Vertex Pharmaceuticals's environmental score of 5.65 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.22/100
Vertex Pharmaceuticals's social score of 24.22 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.46/100
Vertex Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Vertex Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Vertex Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Vertex Pharmaceuticals has, for the most part, managed to keep its nose clean.
Vertex Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 30.84 |
|---|---|
| Total ESG percentile | 44 |
| Environmental score | 5.65 |
| Environmental score percentile | 8 |
| Social score | 24.22 |
| Social score percentile | 8 |
| Governance score | 12.46 |
| Governance score percentile | 8 |
| Level of controversy | 2 |
We're not expecting Vertex Pharmaceuticals to pay a dividend over the next 12 months.
Vertex Pharmaceuticals's shares were split on a 2:1 basis on 23 August 2000 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Vertex Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Vertex Pharmaceuticals shares which in turn could have impacted Vertex Pharmaceuticals's share price.
Over the last 12 months, Vertex Pharmaceuticals's shares have ranged in value from as little as $341.9 up to $519.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vertex Pharmaceuticals's is 0.394. This would suggest that Vertex Pharmaceuticals's shares are less volatile than average (for this exchange).
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG. ; Moderna, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.